Heads Up: We’re Initiating Coverage on NanoViricides (NYSE: NNVC) Starting Tomorrow Morning

*Sponsored Pssst…. Krypton Street Is Initiating Coverage On NanoViricides (NYSE: NNVC) Starting Tomorrow Morning—Friday, April 25, 2025. Here’s What We Can Tell You—So Far… Approximate 57% Move From $0.94 To $1.48 In Six Days Pushed (NNVC) To The Top Of Tomorrow’s Watchlist. Public Float Under 16M Shares Suggests There’s The Potential For Significant Swings If Demand Begins To Shift. Market Cap Under $21M Places (NNVC) In A Category Where It Could Witness A Higher Potential For Growth Compared To Larger Companies In The Same Space. Nanoviricide® Platform Designed To Neutralize Vi-rus-es Using A Method That Does Not Rely On Immune System Activation. NV-387 Has Cleared Phase 1 Without Adverse Events And Is Preparing For Phase 2 With A Focus On Respiratory And Emerging Vi-rus Targets. NV-HHV-101 Is Moving Toward Human Trials With Potential Across Major Topical And Ocular Health Segments. Company Owns A Debt-Free, cGMP Manufacturing Facility Equipped To Support Development Through Human Trial Stages. April 24, 2025 Dear Reader, In biotech, the most disruptive advances don’t begin with headlines—they begin with deep science, strategic vision, and the ability to move fast when the moment calls for it.   NanoViricides (NYSE: NNVC) may not be a household name yet, but its recent approximate 57% move—from $.94 on April 9th to $1.48 by April 16th—caught our attention for a reason. With fewer than 16M shares available in the float and a market cap under $21M, NanoViricides (NYSE: NNVC) operates with a lean structure that has the potential to respond swiftly to changing demand.  Companies of this size, especially in the biotech sector, can witness significant swings if interest begins to shift.  And right now, (NNVC) appears to be flying under the radar—an often-overlooked name in a space dominated by larger players.  But with this type of setup, smaller entities often have a clearer runway for growth and strategic execution. Now, with a fresh open at $1.36 and real-world urgency unfolding in places like Texas and Alabama, NanoViricides (NYSE: NNVC) just shot to the top of our watchlist. This company isn’t just adapting to a changing health landscape—it’s building for it. The Shift: Urgency Meets Innovation With cases in Texas surpassing 600—including tragic outcomes among school-aged children—the healthcare system is again under intense strain.  The CDC has mobilized teams in the region, highlighting the growing severity.  This backdrop places renewed focus on entities capable of delivering rapid, scientifically grounded responses. NanoViricides (NYSE: NNVC) is advancing NV-387, a promising broad-spectrum treatment developed using their proprietary nanoviricide® technology. Designed to mimic human cell receptors, this unique approach neutralizes vi-rus-es before they can replicate—without relying on immune system support.  In a time where emerging strains challenge traditional treatments, this method offers a fresh angle. Inside of NanoViricides (NYSE: NNVC)... Behind the scenes, NanoViricides (NYSE: NNVC) owns a mortgage-free, cGMP-certified manufacturing facility in Shelton, CT.  It’s fully equipped to handle both dr-ug substance and product for clinical supply, allowing the company to reduce costs, avoid delays, and accelerate progress. Beyond NV-387, their pipeline includes NV-HHV-101—targeting shingles and other herpes-related conditions.  NV-HHV-101 has shown positive tolerability in studies and is advancing toward human trials. The Science That Stands Apart … NanoViricides (NYSE: NNVC)’s proprietary nanoviricide® platform is more than an innovation—it’s a departure from the usual path.  Traditional treatments rely on antibodies or other methods that target only parts of a vi-rus, which can be circumvented through mutation. Nanoviricides, on the other hand, replicate the surface of human cells, tricking vi-rus-es into binding as if they were entering a host.  Once attached, the nanoviricide engulfs and dismantles the vi-rus—no immune response required. This bind-encapsulate-destroy approach creates a therapeutic pathway that is less vulnerable to vi-rus adaptation. The company’s development model is lean and precise.  Rather than running costly internal labs, (NNVC) collaborates with academic and government labs for independent testing, ensuring transparent data and efficient capital use. With $10B Market Potential, NanoViricides (NYSE: NNVC) Eyes  Major Breakthrough… NanoViricides (NYSE: NNVC) is a leader in developing nanomedicine dr-ugs to target vir-uses using its nanoviricide® technology.  This technology mimics host cell receptors to trick vir-uses into binding to the nanoviricide, dismantling them and blocking reinfection, providing a more durable solution than traditional antibodies or vax's. Key points: FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides (NYSE: NNVC) Is Topping Our Watchlist Tomorrow Morning… 1. Recent Market Recognition: Approximate 57% move in 6 days—from $.94 on April 9 to $1.48 on April 16, 2025, moved (NNVC) directly to the top of our radar. 2. Limited Float: With fewer than 16M shares available in the float, there’s the potential for significant swings if demand begins to shift. 3. Under The Radar: With a market cap under $21M, (NNVC) could have a higher potential for growth compared to larger companies in the same space. 4. Platform Advantage: Proprietary nanoviricide® technology designed to neutralize vi-rus-es with a post-immunotherapeutic approach. 5. NV-387 Progress: Completed Phase 1 with no adverse events; advancing toward Phase 2 for respiratory and emergent vi-rus targets. 6. FDA Pipeline Advancement: NV-HHV-101 Has Gained Early-Stage Validation Through Encouraging Feedback From The FDA. 7. In-House Infrastructure: Mortgage-free cGMP facility enables efficient, clinical-grade manufacturing in Shelton, CT. All Eyes On NanoViricides (NYSE: NNVC) Friday Morning… In a year that has already seen the largest measles outbreak in Texas in over three decades—with over 600 confirmed cases and two school-aged deaths—NanoViricides (NYSE: NNVC)’s urgency is matched by the real-world need.  Public health agencies have allocated significant emergency resources to respond to this outbreak—highlighting the urgent need for frontline innovation. And while many companies are reactive, NanoViricides (NYSE: NNVC) has built a proactive pipeline.  From bird-borne strains to other emerging threats, this is a team working ahead of the curve—with a system designed to adapt to mutation, not be hindered by it. As public attention rises and clinical progress continues, this is one little-known company that could quickly shift from niche to necessary. We’ll have all eyes on (NNVC) tomorrow morning. Consider taking a look at (NNVC) before you shut down for the night. Also—keep an eye out for my morning update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/24/2025 and ending on 04/25/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid twenty two thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/nnvc/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice